Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2440 vs Perjeta in HER2-positive early/locally advanced breast cancer
CTR20201685Phase 3Completed
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of TQB2440 in breast cancer, sponsored by Nanjing Shunxin Pharmaceutical. Started Sep 2020; status: completed.
02
Drugs
TQB2440
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20201685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201685.